First immunotherapy for breast cancer approved! | The Daily Star
12:00 AM, March 31, 2019 / LAST MODIFIED: 12:00 AM, March 31, 2019

Medical Guideline

First immunotherapy for breast cancer approved!

The United States Food and Drug Administration (FDA) has approved the use of Atezolizumab (Tecentriq) to treat unresectable locally advanced or metastatic triple-negative breast cancer in tumors expressing PD-L1.

The immunotherapy had been previously approved for urothelial cancer and non-small cell lung cancer.

Atezolizumab is approved for use with paclitaxel protein-bound.

Roughly 900 patients who had not previously received chemotherapy were randomised to either Atezolizumab or placebo infusions. All received paclitaxel protein-bound.

Among those with PD-L1-positive tumours, progression-free survival was longer in those receiving Atezolizumab (7.4 vs. 4.8 months for placebo).

Stay updated on the go with The Daily Star Android & iOS News App. Click here to download it for your device.

Grameenphone:
Type START <space> BR and send SMS it to 22222

Robi:
Type START <space> BR and send SMS it to 2222


Banglalink:
Type START <space> BR and send SMS it to 2225

Leave your comments

Top News

Top News

Top